

Improving Outcomes for Patients With Diffuse Large B-

Ca-A Cancer Journal for Clinicians

60, 393-408

DOI: [10.3322/caac.20087](https://doi.org/10.3322/caac.20087)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Newly Emerging Therapies Targeting Viral-Related Lymphomas. <i>Current Oncology Reports</i> , 2011, 13, 416-426.	1.8	21
2	Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. <i>Cancer</i> , 2011, 117, 2530-2540.	2.0	125
3	No Evidence of XMRV or MuLV Sequences in Prostate Cancer, Diffuse Large B-Cell Lymphoma, or the UK Blood Donor Population. <i>Advances in Virology</i> , 2011, 2011, 1-6.	0.5	9
4	Patterns of Social Support Among Lymphoma Patients Considering Stem Cell Transplantation. <i>Social Work in Health Care</i> , 2011, 50, 815-827.	0.8	5
5	Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 2210-2219.	3.2	51
6	Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1577-1585.	0.6	26
7	Initial management strategies for follicular lymphoma. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 35-45.	0.7	10
8	Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1520-1530.	1.1	76
9	Diagnosis and treatment of diffuse large B-cell lymphoma. <i>Swiss Medical Weekly</i> , 2012, 142, w13511.	0.8	27
10	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, 2012, 87.	1.2	17
11	Characteristics and Results of the Management of Diffuse Large B-Cell Lymphomas: The Experience of CÔte d'Ivoire. <i>Advances in Hematology</i> , 2012, 2012, 1-6.	0.6	2
12	Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. <i>Frontiers in Immunology</i> , 2012, 3, 98.	2.2	14
13	Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. <i>British Journal of Haematology</i> , 2012, 158, 608-614.	1.2	31
14	Impact of cutoff age in predicting clinical outcomes of elderly diffuse large B cell lymphoma receiving rituximab or not: A hospital-based study. <i>Journal of Clinical Gerontology and Geriatrics</i> , 2012, 3, 36-41.	0.7	0
15	Extranodal non-Hodgkin's lymphoma in the malar region – a case report. <i>Oral Surgery</i> , 2012, 5, 22-25.	0.1	0
16	Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study. <i>World Journal of Surgical Oncology</i> , 2013, 11, 90.	0.8	22
17	Defining vascular signatures of malignant hepatic masses: role of MDCT with 3D rendering. <i>Abdominal Imaging</i> , 2013, 38, 763-773.	2.0	6
18	Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews. <i>Annals of Hematology</i> , 2013, 92, 1451-1459.	0.8	11

#	ARTICLE	IF	CITATIONS
19	Diffuse Large B-Cell Lymphoma. , 2013, , 427-438.		0
20	Examining racial differences in diffuse large B-cell lymphoma presentation and survival. <i>Leukemia and Lymphoma</i> , 2013, 54, 268-276.	0.6	50
21	Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 3309-3317.	2.0	25
22	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013, 98, 1732-1738.	1.7	54
23	Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. <i>Cancer Imaging</i> , 2013, 13, 53-62.	1.2	36
24	New Insights into the Role of the Immune Microenvironment in Breast Carcinoma. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	50
25	Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood Research</i> , 2014, 49, 162.	0.5	15
26	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 15-25.	0.9	98
27	Insurance status is related to diffuse large B-cell lymphoma survival. <i>Cancer</i> , 2014, 120, 1220-1227.	2.0	47
28	Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. <i>Journal of Hematology and Oncology</i> , 2014, 7, 11.	6.9	176
29	Suboptimal use of imaging in the new (National Comprehensive Cancer Network) International Prognostic Index for diffuse large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 806-807.	3.3	1
30	Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression. <i>International Journal of Hematology</i> , 2014, 99, 79-86.	0.7	8
31	FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 565-574.	3.3	135
32	Bone marrow ¹⁸ F-fluoro-2-deoxy-2-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 726-731.	2.0	70
33	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
34	Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 460-467.e2.	0.2	86
35	C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPi score in diffuse large B-cell lymphoma patients. <i>British Journal of Cancer</i> , 2014, 111, 55-60.	2.9	48
36	Socioeconomic disparities in lymphoma. <i>Blood</i> , 2014, 123, 3530-3531.	0.6	25

#	ARTICLE	IF	CITATIONS
37	Primary skeletal muscle diffuse large B cell lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2015, 10, 2156-2160.	0.8	15
38	Disparities in survival by insurance status in patients with Hodgkin lymphoma. <i>Cancer</i> , 2015, 121, 3515-3524.	2.0	44
39	The use of Yttrium-90 Ibritumomab Tiuxetan (90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. <i>Wspolczesna Onkologia</i> , 2015, 1, 43-47.	0.7	2
40	Prognostic superiority of the international comprehensive cancer network pretreatment whole-body volumetric metabolic PET/CT metrics in diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 532-539.	1.1	58
41	Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma. <i>European Journal of Radiology</i> , 2015, 84, 372-377.	1.2	29
42	Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study. <i>Hematological Oncology</i> , 2015, 33, 42-47.	0.8	8
43	Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2015, 121, 1800-1808.	2.0	54
44	New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 531-544.	1.1	66
45	Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2015, 170, 185-191.	1.2	57
46	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2443-2457.	1.1	8
47	Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma. <i>CNS Oncology</i> , 2015, 4, 131-135.	1.2	4
48	Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 671-679.	0.2	17
49	Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. <i>Medical Oncology</i> , 2015, 32, 446.	1.2	57
50	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. <i>Cancer Cytopathology</i> , 2016, 124, 135-143.	1.4	30
51	The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 326-330.	1.0	15
52	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
53	B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. <i>Expert Review of Hematology</i> , 2016, 9, 553-561.	1.0	8
54	Successful Robotic Excision and Early Chemotherapy for Primary Cardiac Lymphoma. <i>Annals of Thoracic Surgery</i> , 2016, 102, 304-305.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2016, 122, 3145-3151.	2.0	61
56	Diffuse Large B-Cell Lymphoma of the Peri-Implant Mucosa Mimicking Peri-Implantitis. <i>Journal of Oral Implantology</i> , 2016, 42, 220-223.	0.4	4
57	Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 842-851.	0.6	7
58	Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. <i>Hematological Oncology</i> , 2017, 35, 151-157.	0.8	12
59	Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. <i>Molecular and Clinical Oncology</i> , 2017, 6, 627-633.	0.4	7
60	Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?. <i>Cancer</i> , 2017, 123, 3222-3225.	2.0	10
61	Pretransplant ^{18}F -FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2017, 98, 337-347.	1.1	6
62	Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7441-E7449.	3.3	28
63	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
64	Tumor and bone marrow uptakes on $[^{18}F]$ fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. <i>Medicine (United States)</i> , 2017, 96, e8655.	0.4	5
65	Prevalence of BCL-2/((H) Translocation in Healthy African Americans. <i>Annals of Hematology</i> , 2017, 96, 51-55.	0.8	1
66	MicroRNA-21 regulates the viability and apoptosis of diffuse large B-cell lymphoma cells by upregulating B cell lymphoma-2. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 4489-4496.	0.8	15
67	Prognostic significance of retention index of bone marrow on dual-phase ^{18}F -fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2018, 97, e9513.	0.4	7
69	Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 951-961.	1.1	34
70	Informatics Approaches to Address New Challenges in the Classification of Lymphoid Malignancies. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-9.	1.0	2
71	Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis. <i>Cancer Cell International</i> , 2018, 18, 119.	1.8	35
72	Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients. <i>Current Treatment Options in Oncology</i> , 2018, 19, 50.	1.3	8
73	Microtubule-Actin Crosslinking Factor 1 and Plakins as Therapeutic Drug Targets. <i>International Journal of Molecular Sciences</i> , 2018, 19, 368.	1.8	10

#	ARTICLE	IF	CITATIONS
74	Prognostic Value of Bone Marrow FDG Uptake Pattern of PET/CT in Newly Diagnosed Diffuse Large B-cell Lymphoma. <i>Journal of Cancer</i> , 2018, 9, 1231-1238.	1.2	19
75	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 297-306.	1.2	51
76	Similar effectiveness of R-CHOP and R-21 in diffuse large B-cell lymphoma: data from the prospective German Tumour Registry Lymphatic Neoplasms. <i>European Journal of Haematology</i> , 2019, 103, 460-471.	1.1	11
77	Cost burden of diffuse large B-cell lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 645-661.	0.7	14
78	Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 959-973.	1.0	18
79	A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients. <i>Cancer</i> , 2019, 125, 1837-1847.	2.0	12
80	PET-derived tumor metrics predict DLBCL response and progression-free survival. <i>Leukemia and Lymphoma</i> , 2019, 60, 1965-1971.	0.6	17
81	Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1656-1667.	0.6	14
82	Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study. <i>Journal of Internal Medicine</i> , 2019, 285, 455-468.	2.7	27
83	Diffuse Palatal Swelling in a Woman in Her 60s. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 304.	1.2	0
84	Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study. <i>Annals of Translational Medicine</i> , 2020, 8, 1048-1048.	0.7	5
85	Targeting phosphatidylinositol 3 kinase- β and - γ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4382-4392.	2.5	18
86	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2020, 126, 3493-3503.	2.0	15
87	Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2995-3002.	1.2	10
88	A novel classification based on B-cell receptor signal gene expression correlates with prognosis in primary breast diffuse large B-cell lymphoma. <i>Journal of Cancer</i> , 2020, 11, 2431-2441.	1.2	3
89	Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. <i>JAMA Network Open</i> , 2020, 3, e202072.	2.8	74
90	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
91	EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2020, 25, 894-902.	1.9	37

#	ARTICLE	IF	CITATIONS
92	Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. <i>Blood Cancer Journal</i> , 2021, 11, 9.	2.8	32
93	CD8 + Tâ€cell percentage increases in diffuse large Bâ€cell lymphoma patients receiving mannatide combined with standard regimens. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 832-837.	0.7	0
94	5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients. <i>Clinical Epigenetics</i> , 2021, 13, 33.	1.8	13
95	RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2021, 10, 2044-2054.	0.4	1
96	Survival Prediction in Patients with Diffuse Large B-cell Lymphoma Using Logistic and Neural Network Models. , 2021, , .		0
97	Imaging features of skeletal muscle lymphoma: a case report and literature review. <i>BMC Medical Imaging</i> , 2021, 21, 136.	1.4	5
98	Viability of diffuse large B-cell lymphoma cells is regulated by kynurenine 3-monooxygenase activity. <i>Oncology Letters</i> , 2021, 22, 790.	0.8	4
99	Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study. <i>Scientific Reports</i> , 2021, 11, 17950.	1.6	1
100	Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 2.	2.8	29
102	Metadherin Contributes to the Pathogenesis of Diffuse Large B-cell Lymphoma. <i>PLoS ONE</i> , 2012, 7, e39449.	1.1	29
103	Comparative RNA-Seq and Microarray Analysis of Gene Expression Changes in B-Cell Lymphomas of <i>Canis familiaris</i> . <i>PLoS ONE</i> , 2013, 8, e61088.	1.1	49
104	PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2017, 12, e0170299.	1.1	21
105	Plasma Factors for the Differentiation of Hodgkinâ€™s Lymphoma and Diffused Large B Cell Lymphoma and for Monitoring Remission. <i>Journal of Hematology (Brossard, Quebec)</i> , 2019, 8, 47-54.	0.4	5
106	Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>European Oncology and Haematology</i> , 2012, 08, 123.	0.0	7
107	Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 83544-83553.	0.8	48
108	Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients. <i>Oncotarget</i> , 2017, 8, 73168-73176.	0.8	9
109	Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients. <i>Oncotarget</i> , 2017, 8, 49757-49772.	0.8	18
110	Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. <i>Oncotarget</i> , 2017, 8, 99587-99600.	0.8	41

#	ARTICLE	IF	CITATIONS
111	Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma. <i>Oncotarget</i> , 2016, 7, 19072-19080.	0.8	13
112	Toxicity and Apoptosis Related Effects of Benzimidazo [3,2- $\hat{1}$] Quinolinium Salts Upon Human Lymphoma Cells. <i>Open Medicinal Chemistry Journal</i> , 2017, 11, 54-65.	0.9	3
113	Diffuse large B-cell lymphoma, not otherwise specified of the palate: a case report. <i>Journal of Clinical and Experimental Dentistry</i> , 2013, 5, e287-90.	0.5	4
114	Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England. <i>British Journal of Cancer</i> , 2022, 126, 134-143.	2.9	10
115	Genetic polymorphism study of the BCL-6 gene, in diffuse large B-cell lymphoma. <i>Saudi Journal for Health Sciences</i> , 2012, 1, 74.	0.1	0
116	Germinal-center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases. <i>Chinese Journal of Cancer</i> , 2013, 32, 561-566.	4.9	0
117	Bone Marrow Involvement in Hodgkin and Non-Hodgkin Lymphomas: The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. <i>Journal of Bone Marrow Research</i> , 2014, 02, .	0.2	1
118	Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes. <i>Journal of Hematology (Brossard, Quebec)</i> , 2017, 6, 33-43.	0.4	5
119	Primary Diffuse Large B-Cell Lymphoma of the Female Urethra: A Case Report and Review of the Literature. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13015-13022.	1.0	1
120	Socioeconomic Inequalities in Treatment and Relative Survival Among Patients With Diffuse Large B-Cell Lymphoma in Hong Kong. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
121	New Challenges in the Management of Diffuse Large B-Cell Lymphoma. <i>Treatment Strategies Hematology</i> , 2012, 2, 68-73.	0.0	2
123	Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 231-8.	1.0	10
124	Sino-nasal T-cell lymphoma invading the brain: A case study. <i>Journal of Innovative Optical Health Sciences</i> , 2014, 9, 235.	0.5	0
125	Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 1313-1327.	2.6	4
126	Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma. <i>Clinical Therapeutics</i> , 2022, , .	1.1	0
127	Sino-nasal T-cell lymphoma invading the brain: A case study. <i>Journal of Innovative Optical Health Sciences</i> , 2014, 9, 235-235.	0.5	0
128	The Role of RNA Methyltransferase METTL3 in Normal and Malignant Hematopoiesis. <i>Frontiers in Oncology</i> , 2022, 12, 873903.	1.3	11
129	Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 596-608.	0.8	7

#	ARTICLE	IF	CITATIONS
130	The Prognostic Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Analyses of Metabolic Response Rates in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
131	Use of benzodiazepines is the risk factor for infection in patients aged 80 years or older with diffuse large B-cell lymphoma: A single-institution retrospective study. <i>PLoS ONE</i> , 2022, 17, e0269362.	1.1	0
132	The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. <i>PLoS ONE</i> , 2022, 17, e0273839.	1.1	1
133	Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , .	0.3	0
134	Targeting MCL ¹ and BCL ² with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. <i>American Journal of Hematology</i> , 2023, 98, 449-463.	2.0	5
135	C.E. Credit. The Synergistic Role of 2D and 3D Imaging in Evaluating Tumors of the Jaws: A Case Report of Diffuse Large B-Cell Lymphoma of the Mandible. <i>Journal of the California Dental Association</i> , 2022, 50, 519-525.	0.0	0
136	Prognostic Significance of Ribosome-related Genes Signature in Diffuse Large B Cell Lymphoma. <i>Journal of Cancer</i> , 2023, 14, 403-416.	1.2	0
138	Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma. <i>Diagnostics</i> , 2023, 13, 861.	1.3	3
139	Lymphocyte to monocyte ratio predicts survival and is epigenetically linked to miR-222-3p and miR-26b-5p in diffuse large B cell lymphoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	0